Variant Summary
- HGVS
- —
- Variant Type(s)
- protein_altering_variant
- Evidence Items
- 13
Evidence Level Distribution
Level B: 11Level D: 2
Evidence Items
Showing CIViC evidence rows where gene = KRAS and variant = G12/G13.
| Level | Type | Direction | Significance | Disease | Drugs | Rating |
|---|---|---|---|---|---|---|
| B | Predictive | Supports | Resistance | Pancreatic Adenocarcinoma | Trametinib,Gemcitabine | 4 |
| B | Predictive | Supports | Resistance | Colorectal Cancer | Cetuximab,Chemotherapy | 3 |
| D | Predictive | Supports | Resistance | Colorectal Cancer | Cetuximab | 3 |
| D | Prognostic | Supports | Poor Outcome | Colorectal Cancer | 3 | |
| B | Predictive | Supports | Resistance | Colorectal Cancer | Panitumumab | 3 |
| B | Prognostic | Does Not Support | Poor Outcome | Colorectal Cancer | 3 | |
| B | Predictive | Supports | Resistance | Lung Non-small Cell Carcinoma | Erlotinib,Gefitinib | 3 |
| B | Prognostic | Does Not Support | Poor Outcome | Colorectal Cancer | 3 | |
| B | Predictive | Does Not Support | Resistance | Colorectal Cancer | Oxaliplatin | 3 |
| B | Predictive | Does Not Support | Resistance | Colorectal Cancer | Irinotecan | 3 |
| B | Predictive | Does Not Support | Resistance | Colorectal Cancer | Bevacizumab | 3 |
| B | Predictive | Supports | Resistance | Colorectal Cancer | Cetuximab,Panitumumab | 3 |
| B | Predictive | Does Not Support | Sensitivity/Response | Pancreatic Adenocarcinoma | Trametinib | 3 |